Literature DB >> 29385432

Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension.

Kurt R Stenmark1, Maria G Frid1, Brian B Graham2, Rubin M Tuder2.   

Abstract

Pulmonary hypertension (PH) is the end result of interaction between pulmonary vascular tone and a complex series of cellular and molecular events termed 'vascular remodelling'. The remodelling process, which can involve the entirety of pulmonary arterial vasculature, almost universally involves medial thickening, driven by increased numbers and hypertrophy of its principal cellular constituent, smooth muscle cells (SMCs). It is noted, however that SMCs comprise heterogeneous populations of cells, which can exhibit markedly different proliferative, inflammatory, and extracellular matrix production changes during remodelling. We further consider that these functional changes in SMCs of different phenotype and their role in PH are dynamic and may undergo significant changes over time (which we will refer to as cellular plasticity); no single property can account for the complexity of the contribution of SMC to pulmonary vascular remodelling. Thus, the approaches used to pharmacologically manipulate PH by targeting the SMC phenotype(s) must take into account processes that underlie dominant phenotypes that drive the disease. We present evidence for time- and location-specific changes in SMC proliferation in various animal models of PH; we highlight the transient nature (rather than continuous) of SMC proliferation, emphasizing that the heterogenic SMC populations that reside in different locations along the pulmonary vascular tree exhibit distinct responses to the stresses associated with the development of PH. We also consider that cells that have often been termed 'SMCs' may arise from many origins, including endothelial cells, fibroblasts and resident or circulating progenitors, and thus may contribute via distinct signalling pathways to the remodelling process. Ultimately, PH is characterized by long-lived, apoptosis-resistant SMC. In line with this key pathogenic characteristic, we address the acquisition of a pro-inflammatory phenotype by SMC that is essential to the development of PH. We present evidence that metabolic alterations akin to those observed in cancer cells (cytoplasmic and mitochondrial) directly contribute to the phenotype of the SM and SM-like cells involved in PH. Finally, we raise the possibility that SMCs transition from a proliferative to a senescent, pro-inflammatory and metabolically active phenotype over time.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29385432      PMCID: PMC5852549          DOI: 10.1093/cvr/cvy004

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  139 in total

Review 1.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; Elvira Stacher; Jeffrey Robinson; Rahul Kumar; Brian B Graham
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

Review 2.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

3.  Glucose-6-phosphate dehydrogenase plays a critical role in hypoxia-induced CD133+ progenitor cells self-renewal and stimulates their accumulation in the lungs of pulmonary hypertensive rats.

Authors:  Sukrutha Chettimada; Sachindra Raj Joshi; Abdallah Alzoubi; Sarah A Gebb; Ivan F McMurtry; Rakhee Gupte; Sachin A Gupte
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-07-25       Impact factor: 5.464

Review 4.  Mitochondria in vascular health and disease.

Authors:  Peter Dromparis; Evangelos D Michelakis
Journal:  Annu Rev Physiol       Date:  2012-11-16       Impact factor: 19.318

5.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation.

Authors:  Ruoning Wang; Christopher P Dillon; Lewis Zhichang Shi; Sandra Milasta; Robert Carter; David Finkelstein; Laura L McCormick; Patrick Fitzgerald; Hongbo Chi; Joshua Munger; Douglas R Green
Journal:  Immunity       Date:  2011-12-23       Impact factor: 31.745

6.  Peg3/Pw1 is an imprinted gene involved in the TNF-NFkappaB signal transduction pathway.

Authors:  F Relaix; X J Wei; X Wu; D A Sassoon
Journal:  Nat Genet       Date:  1998-03       Impact factor: 38.330

7.  Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease.

Authors:  Laurent Savale; Ari Chaouat; Sylvie Bastuji-Garin; Elisabeth Marcos; Laurent Boyer; Bernard Maitre; Mourad Sarni; Bruno Housset; Emmanuel Weitzenblum; Mireille Matrat; Philippe Le Corvoisier; Dominique Rideau; Jorge Boczkowski; Jean-Luc Dubois-Randé; Christos Chouaid; Serge Adnot
Journal:  Am J Respir Crit Care Med       Date:  2009-01-29       Impact factor: 21.405

8.  Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment.

Authors:  Ok Hee Jeon; Chaekyu Kim; Remi-Martin Laberge; Marco Demaria; Sona Rathod; Alain P Vasserot; Jae Wook Chung; Do Hun Kim; Yan Poon; Nathaniel David; Darren J Baker; Jan M van Deursen; Judith Campisi; Jennifer H Elisseeff
Journal:  Nat Med       Date:  2017-04-24       Impact factor: 53.440

9.  The effect of continued hypoxia on rat pulmonary arterial circulation. An ultrastructural study.

Authors:  B Meyrick; L Reid
Journal:  Lab Invest       Date:  1978-02       Impact factor: 5.662

10.  Enhanced growth capacity of neonatal pulmonary artery smooth muscle cells in vitro: dependence on cell size, time from birth, insulin-like growth factor I, and auto-activation of protein kinase C.

Authors:  E C Dempsey; D B Badesch; E L Dobyns; K R Stenmark
Journal:  J Cell Physiol       Date:  1994-09       Impact factor: 6.384

View more
  29 in total

Review 1.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Perspective: pathobiological paradigms in pulmonary hypertension, time for reappraisal.

Authors:  Rubin M Tuder; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-03-18       Impact factor: 5.464

3.  Pluripotent hematopoietic stem cells augment α-adrenergic receptor-mediated contraction of pulmonary artery and contribute to the pathogenesis of pulmonary hypertension.

Authors:  Ryota Hashimoto; Gregg M Lanier; Vidhi Dhagia; Sachindra R Joshi; Allan Jordan; Ian Waddell; Rubin Tuder; Kurt R Stenmark; Michael S Wolin; Ivan F McMurtry; Sachin A Gupte
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-01-08       Impact factor: 5.464

4.  Endothelial platelet-derived growth factor-mediated activation of smooth muscle platelet-derived growth factor receptors in pulmonary arterial hypertension.

Authors:  Kang Wu; Haiyang Tang; Ruizhu Lin; Shane G Carr; Ziyi Wang; Aleksandra Babicheva; Ramon J Ayon; Pritesh P Jain; Mingmei Xiong; Marisela Rodriguez; Shamin Rahimi; Francesca Balistrieri; Shayan Rahimi; Daniela Valdez-Jasso; Tatum S Simonson; Ankit A Desai; Joe G N Garcia; John Y-J Shyy; Patricia A Thistlethwaite; Jian Wang; Ayako Makino; Jason X-J Yuan
Journal:  Pulm Circ       Date:  2020-09-10       Impact factor: 3.017

5.  Calcium-channel-blockers exhibit divergent regulation of cancer extravasation through the mechanical properties of cancer cells and underlying vascular endothelial cells.

Authors:  S R Vaibavi; Manoj Sivasubramaniapandian; Rahul Vaippully; Privita Edwina; Basudev Roy; Saumendra Kumar Bajpai
Journal:  Cell Biochem Biophys       Date:  2021-10-13       Impact factor: 2.194

6.  Vascular smooth muscle ROCK1 contributes to hypoxia-induced pulmonary hypertension development in mice.

Authors:  Krishna C Penumatsa; Adit A Singhal; Rod R Warburton; Michael D Bear; Chinmayee D Bhedi; Sabina Nasirova; Jamie L Wilson; Guanming Qi; Ioana R Preston; Nicholas S Hill; Barry L Fanburg; Young-Bum Kim; Deniz Toksoz
Journal:  Biochem Biophys Res Commun       Date:  2022-03-09       Impact factor: 3.322

7.  Implication of in vivo circulating fibrocytes ablation in experimental pulmonary hypertension murine model.

Authors:  Vandana S Nikam; Sandeep Nikam; Akyl Sydykov; Katrin Ahlbrecht; Rory E Morty; Werner Seeger; Robert Voswinckel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

8.  Mural Cell SDF1 Signaling Is Associated with the Pathogenesis of Pulmonary Arterial Hypertension.

Authors:  Ke Yuan; Yu Liu; Yue Zhang; Abinaya Nathan; Wen Tian; Joyce Yu; Andrew J Sweatt; Elya A Shamshou; David Condon; Ananya Chakraborty; Stuti Agarwal; Natasha Auer; Serena Zhang; Joseph C Wu; Roham T Zamanian; Mark R Nicolls; Vinicio A de Jesus Perez
Journal:  Am J Respir Cell Mol Biol       Date:  2020-06       Impact factor: 6.914

9.  iPSC-endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for pulmonary arterial hypertension.

Authors:  Mingxia Gu; Michele Donato; Minzhe Guo; Neil Wary; Yifei Miao; Shuai Mao; Toshie Saito; Shoichiro Otsuki; Lingli Wang; Rebecca L Harper; Silin Sa; Purvesh Khatri; Marlene Rabinovitch
Journal:  Sci Transl Med       Date:  2021-05-05       Impact factor: 17.956

Review 10.  Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension.

Authors:  Cheng-Jun Hu; Hui Zhang; Aya Laux; Soni S Pullamsetti; Kurt R Stenmark
Journal:  J Physiol       Date:  2018-08-07       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.